[Studies on cefozopran in the pediatric field].
Pharmacokinetic and clinical evaluations of cefozopran (CZOP) were carried out in pediatric patients. The following results were obtained: 1. Upon 30-minute intravenous drip infusion at a dose of 20mg/kg, plasma concentrations of CZOP reached their peaks at the end of drip infusion with an average value of 77.1 micrograms/ml, and the average plasma half-life was 1.78 hours in the beta-phase. Upon 30-minute intravenous drip infusion at a dose of 10 mg/kg, peak plasma concentration was 40.5 micrograms/ml and plasma half-life was 1.62 hours. 2. The urinary excretion rates of CZOP after 30-minute intravenous infusion at doses of 20 and 10 mg/kg were 53.2% and 56.2%, respectively. 3. CZOP was administered to 17 cases (upper and lower respiratory tract infections, pneumonia, lymphadenitis and urinary tract infections) at daily doses of 60-90 mg/kg divided into 3 dosages using 30-minute intravenous drip infusion. Clinical responses were "excellent" in 13 patients, "good" in 3, and "poor" in 1, hence the efficacy rate of 94.1% was obtained. 4. Bacteria identified from various disease cases included 19 strains of 8 species, and the eradication rate was 94.7%. 5. Soft stool occurred in 1 case as an adverse reaction. Laboratory test results showed abnormalities in 2 cases with elevation of GOT and GPT.
Department of Pediatrics, Ohguchi Higashi General Hospital.
K
K
Niinou
H
H
Sato
D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D002511:Cephalosporins / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D008297:Male; D000097586:Cefozopran
D002511:Cephalosporins; D000097586:Cefozopran